Peanut Oral Immunotherapy (OIT)

Phase 2

NNational Institute of Allergy and Infectious Diseases (NIAID)

Peanut Oral Immunotherapy (OIT) is one of 2 therapeutic programs targeting Peanut Allergy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Peanut AllergyRecruiting

Peanut AllergyPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Peanut Allergy

#DrugCompanyPhaseTrials

Tezspire

AstraZeneca

Phase 2

1 2

Peanut Oral Immunotherapy (OIT)

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Peanut Allergy

NCT07015996

Clinical

Trials by Indication[1]

Peanut Allergy1 trial

Efficacy of Tezepelumab in Peanut Oral Immunotherapy: a Double-Blind, Randomized, Placebo-Controlled Trial

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07015996·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Peanut Oral Immunotherapy (OIT). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Peanut Oral Immunotherapy (OIT). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Peanut Oral Immunotherapy (OIT)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Peanut Allergy1 trial

References

Drug Info

Quick Facts

Related News